ACM
BBIO icon

ADAR1 Capital Management’s BridgeBio Pharma BBIO Stock Holding History

ADAR1 Capital Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,200
Closed -$30.4K – 290
2024
Q2 		$30.4K Hold
1,200
– – 0.01% 205
2024
Q1 		$37.1K Buy
+1,200
New +$40.8K 0.01% 197

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ADAR1 Capital Management's BBIO Position: Q1 2026 in Review

ADAR1 Capital Management reduced its BridgeBio Pharma (BBIO) stake by 56% in Q1 2026, selling an estimated $8.63M and leaving 94,292 shares worth $7M. The position accounts for 0.41% of the portfolio, ranked #59.

ADAR1 Capital Management first reported a position in BBIO in Q4 2023 and has held it in 10 quarters since. The position peaked at $36.9M in Q3 2024. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • ADAR1 Capital Management held 94,292 shares of BridgeBio Pharma worth $7M as of Q1 2026.
  • ADAR1 Capital Management sold 119,122 BridgeBio Pharma shares in Q1 2026, an estimated $8.63M.
  • BridgeBio Pharma made up 0.41% of ADAR1 Capital Management's portfolio in Q1 2026, its #59 holding.
  • ADAR1 Capital Management first reported a position in BridgeBio Pharma in Q4 2023 and has held it in 10 quarters since.
  • ADAR1 Capital Management's BridgeBio Pharma position peaked at $36.9M in Q3 2024.
  • 457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.